Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks

Federico Pulido(Bellvitge University Hospital), Cristina E. Pharo(GlaxoSmithKline (United Kingdom)), Andreas Plettenberg(Institute for Interdisciplinary Medicine), Knud Schewe(Robert Koch Institute), Cindy Vavro(Research Triangle Park Foundation), Ken Logue(St. Clair College), Dan Duiculescu(Clinical Emergency Hospital Bucharest), Michael L. Lim(GlaxoSmithKline (United Kingdom)), J.G. Baril, Linda H. Y. Yau(Research Triangle Park Foundation), Vicente Estrada(Instituto de Salud Carlos III)
HIV Clinical Trials
April 1, 2009
10.1310/hct1002-76
Cited by 32

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343
Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals
|Mucosal Immunology|2014|332